ArticleArthritis research & therapy2019
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
Article in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease.Frontiers in medicine · 2020Pooled it
- Vitamin D and bone health in psoriatic arthritis: bone mineral density, turnover markers, and biochemical measures.Wiener medizinische Wochenschrift (1946) · 2026Article
- Effect of abatacept on bone in patients with psoriatic arthritis-results from a prospective interventional high-resolution imaging study (ABEPSA).EULAR rheumatology open · 2026Article
- Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study.Arthritis research & therapy · 2026Article
- Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study.RMD open · 2026Article
- The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects.Rheumatology and therapy · 2025Review
- [Systemic versus local demineralization in rheumatoid arthritis : Insights into the bone].Zeitschrift fur Rheumatologie · 2025Review
- Unconventional Imaging Methods in Psoriatic Arthritis.Current rheumatology reports · 2025Review
- Imaging in inflammatory arthritis: progress towards precision medicine.Nature reviews. Rheumatology · 2023Review
- The risk of osteopenia/osteoporosis and psoriatic disease: A systematic review.Skin health and disease · 2023Article
- How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management.Current rheumatology reports · 2023Review
- Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.Therapeutic advances in musculoskeletal disease · 2023Review
- Psoriasis and osteoporosis: a literature review.Clinical and experimental dermatology · 2022Review
- Psoriatic arthritis from a mechanistic perspective.Nature reviews. Rheumatology · 2022Review
- Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.Nature reviews. Rheumatology · 2022Review
- Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis.International journal of molecular sciences · 2022Review
- Clinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy.Calcified tissue international · 2021Article
- The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.Frontiers in endocrinology · 2021Review
- Applying precision medicine to unmet clinical needs in psoriatic disease.Nature reviews. Rheumatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo address whether the use of methotrexate (MTX) and biological disease-modifying anti-rheumatic drugs (bDMARDs) impacts bone structure and biomechanical properties in patients with psoriatic arthritis (PsA).
methodsThis is a cross-sectional study in PsA patients receiving no DMARDs, MTX, or bDMARDs. Volumetric bone mineral densities (vBMDs), microstructural parameters, and biomechanical properties (stiffness/failure load) were determined by high-resolution peripheral quantitative CT and micro-finite element analysis in the respective groups. Bone parameters were compared between PsA patients with no DMARDs and those receiving any DMARDs, MTX, or bDMARDs, respectively.
resultsOne hundred sixty-five PsA patients were analyzed, 79 received no DMARDs, 86 received DMARDs, of them 52 bDMARDs (TNF, IL-17- or IL-12/23 inhibitors) and 34 MTX. Groups were balanced for age, sex, comorbidities, functional index, and bone-active therapy, while disease duration was longest in the bDMARD group (7.8 ± 7.4 years), followed by the MTX group (4.6 ± 7.4) and the no-DMARD group (2.9 ± 5.2). No difference in bone parameters was found between the no-DMARD group and the MTX group. In contrast, the bDMARD group revealed significantly higher total (p = 0.001) and trabecular vBMD (p = 0.005) as well as failure load (p = 0.012) and stiffness (p = 0.012). In regression models, age and bDMARDs influenced total vBMD, while age, sex, and bDMARDs influenced failure load and stiffness.
conclusionDespite longer disease duration, bDMARD-treated PsA patients benefit from higher bone mass and better bone strength than PsA patients receiving MTX or no DMARDs. These data support the concept of better control of PsA-related bone disease by bDMARDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.